# Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer

> **NIH NIH R44** · METACLIPSE THERAPEUTICS CORPORATION · 2022 · $34,640

## Abstract

Abstract of the supplemental grant:
Breast cancer accounts for the highest cancer-related mortality in women. Among its subtypes, metastatic triple
negative breast cancer (TNBC) has the worst prognosis largely due to resistance to currently available therapies
and lack of estrogen receptor, progesterone receptor and HER-2 protein expression. Recent studies employing
immune checkpoint inhibitor (ICI) therapies suggest that TNBC may be a good target for ICI therapy due to the
presence of high level of infiltrating lymphocytes. However, the majority of the TNBC cancer patients do not
respond to ICI therapy due to the lack of pre-existing immunity. In order to develop more effective treatments, it
is important to design a therapeutic approach for TNBC patients which overcomes intra-tumoral and inter-patient
heterogeneity. Metaclipse Therapeutics has been engaged in developing a personalized vaccine to address
heterogeneity. Utilizing a novel protein transfer method, we generate tumor membrane vesicles (TMVs) derived
from whole tumor tissues and modify them with glycolipid-anchored forms of immunostimulatory molecules (GPI-
ISMs) expressing B7-1 and interleukin-12 (IL-12). Our data demonstrates that TMV vaccines prepared from
syngeneic tumors are effective in multiple murine models of cancer. However, it is currently unknown if
neoadjuvant chemotherapy which is a standard of care for breast cancer affects the yield and quality of TMV-
based vaccines. We hypothesize that the addition of standard-of-care (SOC) chemotherapy which is usually
administered in TNBC patients before surgery impacts the yield and quality of TMV-based vaccines. To address
this, the following specific aims are proposed. Aim 1, To define the impact of neoadjuvant chemotherapy on the
yield and quality of the TMV vaccine. Aim 2, To define the impact of neoadjuvant chemotherapy on the ability of
TMV vaccine to stimulate APCs and autologous T cells ex vivo. The parent grant of this supplement proposal
will be conducting Phase 1 clinical trial to evaluate the tolerability of TMV vaccine in TNBC patients. This study
will provide an understanding about how the neoadjuvant chemotherapy impacts the TMV-based vaccines
prepared from TNBC tumors.

## Key facts

- **NIH application ID:** 10551635
- **Project number:** 3R44CA257278-01A1S1
- **Recipient organization:** METACLIPSE THERAPEUTICS CORPORATION
- **Principal Investigator:** CHRISTOPHER D PACK
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $34,640
- **Award type:** 3
- **Project period:** 2022-02-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10551635

## Citation

> US National Institutes of Health, RePORTER application 10551635, Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer (3R44CA257278-01A1S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10551635. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*